The global fungal keratitis treatment market size to grow to USD 1323 million in 2030 at a CAGR of 6% from the early market figures of USD 777 million in 2021. North America has a dominance in the market, with the market valued at USD 274 million in 2021 and expected to reach at USD 440 million in 2030 at a CAGR of 5%.
New York, United States, July 14, 2022 (GLOBE NEWSWIRE) -- The fungal keratitis treatment market is driven by the increasing prevalence of such diseases worldwide, rising awareness of the potential risks posed by fungal keratitis, and advances in its therapeutics. Aspergillus species are the most common causal agent of fungal keratitis, a condition that is becoming increasingly prevalent. Risk factors for fungal keratitis include trauma, contact lens wear, topical corticosteroid use, diabetes mellitus, and low socioeconomic status.
Increasing research activities to develop novel therapeutics and rising sales volume of ophthalmic drugs for fungal keratitis disorders are anticipated to be one of the most significant market drivers over the forecast period. Government initiatives, such as awareness campaigns may also contribute to the expansion of the market for fungal keratitis treatment.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/fungal-keratitis-treatment-market/request-sample
Growing Burden of Fungal Keratitis Disease and Increase in Research and Development Activities Proving to be the Key Drivers for the Fungal Keratitis Treatment Market Growth
Infection of the cornea, a transparent dome covering the colored portion of the eye, is a fungus-caused keratitis. Fusarium, Aspergillus, and Candida species are some fungi known to cause fungal infections frequently. This condition can result in eye pain, redness, blurred vision, sensitivity to light, excessive tearing, and eye discharge. In addition, the increasing prevalence of fungal keratitis around the world has a positive impact on the market's growth as a whole. The highest ratio of fungi to bacteria as a cause of microbial keratitis is observed in subtropical and tropical countries, primarily among male agricultural workers.
As the number of contact lens wearers rise, the prevalence of fungal keratitis increases. The most prevalent predisposing risk factors for infection are the use of contact lenses, associated poor hygiene, and exposure to water sources containing amoebas. Consequently, the increasing number of contact lens wearers exposed to the risk of fungal keratitis drives the expansion of the market. Consequently, based on the aforementioned factors, it is evident that the burden of fungal keratitis is increasing, thereby contributing to the expansion of the studied market.
Increased Research and Development Activities Contribute to the Market Expansion
The development and discovery of new antifungal treatments for fungal keratitis is the subject of numerous efforts. In addition, the research institutes will likely initiate the next phase of trials in the near future. Thus, the positive outcomes of such trials may result in the creation of a new treatment, which could stimulate market growth in the coming years. Nanoparticle-based product development is likely to facilitate market expansion.
Researchers reportedly developed a nanoparticle-based drug delivery system that increases the drug residence time by anchoring the cornea, reducing inflammation, and releasing the antifungal medication in response to environmental conditions. Significantly increased corneal retention decreased inflammation, and resolution of infection is observed in infected eyes. Numerous breakthrough innovations of highly effective drugs against various fungal keratitis diseases have resulted from these research advancements, leading the majority of investors to favor investing in R&D and contributing to market expansion. As a result of the aforementioned factors, the market is likely to expand at a faster rate in the coming years.
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
By Route of Administration, By Distribution Channel, By Region
North America, Europe, Asia-Pacific, LAME and Rest of the World
Alvogen, Bausch health Companies Inc, Gilead Biosciences Inc, Glenmark Pharmaceuticals, Leadiant Biosciences, Merck & Co. Inc., Aurolab, Eyevance Pharmaceuticals LLC, Pfizer Inc
Increase in Research and Development Activities to Boost Fungal Keratitis Treatment Market
Growing Burden of Fungal Keratitis Disease and Increase in Research and Development Activities Proving to be the Key Drivers for the Fungal Keratitis Treatment Market Growth
Buy Now Full Report @ https://straitsresearch.com/buy-now/fungal-keratitis-treatment-market
Impact of Covid-19 on the Global Market Fungal Keratitis Treatment Market -
A stringently monitored public health policy consisting of travel restrictions and general closures was implemented on a massive scale during the initial period. Nonetheless, numerous repercussions were inevitable. Two of the most prevalent methods for preventing the spread of COVID-19 are avoiding non-essential doctor visits and subsequently reducing prescriptions.
Despite the fact that a number of drugs have been approved for sale, it is anticipated that their production will be slowed during pandemic times due to a labor shortage. Clinical trials of approved drugs for other indications and new drugs are being slowed because many companies have delayed the majority of new studies in a number of countries. The shortage of both resources and patients is the primary cause.
Furthermore, biopharmaceutical companies cannot add to the burden of clinical trials and the production of approved drugs because healthcare facilities are already overburdened with saving the lives of COVID patients. Consequently, the impact of COVID-19 on the market's growth may become apparent this year due to a decline in eye care consultations. In the near future, the market may also experience normal growth.
Regional Analysis of the Global Fungal Keratitis Treatment Market –
The global fungal keratitis treatment market is primarily divided into three regions, North America, Europe, and Asia. Out of which, North America has a dominance in the market, with the market valued at USD 274 million in 2021 and expected to reach at USD 440 million in 2030 at a CAGR of 5%. Asia-Pacific is the second dominant region that accounts for a market value of USD 198 million in 2021 and reaching at USD 367 million by 2030 at a CAGR of 7%. Among these three regions, the least contributing region is Europe, which accounts for USD 187 million in 2021 and is expected to grow to USD 300 million in 2030 at a CAGR of 5%.
The global fungal keratitis treatment market to grow at USD 1323 million in 2030 at a CAGR of 6.1% from the early market figures of USD 777 million in 2021.
Based on route of administration, the global fungal keratitis treatment market is dominated by the topical route segment, which accounts for a market value of USD 376 million in 2021 and expected to reach at USD 651 million by 2030 at a CAGR of 6%.
By distribution channel, the drug stores dominates the overall market share with the figures of USD 393 million in 2021 and anticipated to grow at USD 659 million by 2030 at a CAGR of 6%.
The global fungal keratitis treatment market is dominated by North America, which had a market value of USD 274 million in 2021 and expected to reach at USD 440 million in 2030 at a CAGR of 5%.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/fungal-keratitis-treatment-market/request-sample
Top Market Key Companies in the Global Fungal Keratitis Treatment Market
Global Fungal Keratitis Treatment Market: Segmentation
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Executive Summary
4 Market Overview
4.1 Report Segmentation & Scope
4.2 Value Chain Analysis: Fungal Keratitis Treatment Market
4.3 Key Market Trends
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.4 Threat of New Entrants
4.5 Environment & Regulatory Landscape
4.6 Forecast Factors & Relevance of Impact
4.7 Macro-Economic & Geopolitical Scenario
4.8 Parent Market Overview
4.9 Technology Landscape
4.10 Market Share Analysis
4.11 Potential Venture Analysis
4.12 Regional Price Trends
4.13 Raw Material Trends
4.14 Cost Structure Analysis
4.14.1 Labor Cost
4.14.2 Consumables
4.14.3 Maintenance Cost
4.15 Covid-19 Impact Analysis:
4.15.1 Pre and Post Covid-19 Market Scenario Analysis
4.15.2 Market Recovery Timeline and Challenge
4.15.3 Measures Taken by Top Players
4.15.4 Quarterly Market Revenue and Growth Forecast till 2021
4.15.4.1 North America
4.15.4.2 Europe
4.15.4.3 Asia-Pacific
4.15.4.4 Central and South America and the Caribbean
4.15.4.5 The Middle East and Africa
5 Route of Administration Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value & Volume)
5.2 Oral
5.2.1 Market Size & Forecast (Value & Volume)
5.3 Injection
5.3.1 Market Size & Forecast (Value & Volume)
5.4 Topical
5.4.1 Market Size & Forecast (Value & Volume)
6 Distribution Channel Overview
6.1 Introduction
6.1.1 Market Size & Forecast (Value & Volume)
6.2 Hospitals
6.2.1 Market Size & Forecast (Value & Volume)
6.3 Drug stores
6.3.1 Market Size & Forecast (Value & Volume)
7 Regional Overview
7.1 Introduction
7.1.1 Market Size & Forecast (Value & Volume)
7.2 North America
7.3 Central and South America and the Caribbean
7.3.6 Rest of Central and South America and the Caribbean
7.4 Europe
7.4.7 The Rest Of Europe
7.5 Asia-Pacific (APAC)
7.6 Middle East
7.6.8 The Rest Of Middle East
7.7 Africa
7.7.5 The Rest Of Africa
8 Competitive Landscape — Manufacturers & Suppliers
8.1 Competition Dashboard
8.2 Industry Structure
8.3 Alvogen
8.4 Bausch Health Companies Inc
8.5 Gilead Biosciences Inc
8.6 Glenmark Pharmaceuticals
8.7 Leadiant Biosciences
8.8 Merck & Co. Inc.
8.9 Aurolab
8.10 Eyevance Pharmaceuticals LLC
9 Conclusion & Recommendation
10 Acronyms & Abbreviations
Table of Content and Figure @https://straitsresearch.com/report/fungal-keratitis-treatment-market/toc
In April 2020, Alvogen partnered with Yas holding and announced their license and distribution agreement to commercialize generics portfolio.
In March 2019, Bausch health companies Inc. completed acquisition of certain assets of Synergy pharmaceuticals of about USD 195 million.
In July 2019, Merck & Co. Inc acquired Peloton Therapeutics for a value of USD 1.01 billion.
In October 2019, Eyevance Pharmaceuticals LLC acquired Tobradex ST for their future expansion in various regions of the world.
Top 7 Players in the Global Ventilators Market
How Could Gene Therapy Overcome Difficulties in Cancer Treatment.
India Cancer Market is Registering Over 1 Million New Cases Every Year
Here is All You Need to Know About Cancer
Have a Look at the Related Research Report
Aesthetic Medicine Market: Information by Procedure Type (Invasive Procedures, Non-Invasive Procedures), and Region — Forecast till 2030
Veterinary Oncology Market: Information by Therapy (Surgery, Radiology, Chemotherapy), Animal Type (Canine, Feline), Cancer Type (Lymphoma, Mammary), and Region—Forecast till 2029
Acute Sinusitis Market: Information by Treatment (Diagnosis, Medication) and End-User (Hospital & Clinics, ENTC Specialists, Research Institutes) —Forecast Till 2026
Tumor Ablation Market: Information by Technology (Microwave Ablation), Treatment (Surgical, Laparoscopic), Application (Kidney Cancer, Liver Cancer), and Region — Forecast till 2030
About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
(Reuters) -The judge overseeing Twitter Inc's $44 billion lawsuit against Elon Musk has a no-nonsense reputation as well as the distinction of being one of the few jurists who has ever ordered a reluctant buyer to close a U.S. corporate merger. Kathaleen McCormick took over the role of chancellor or chief judge of the Court of Chancery last year, the first woman in that role. On Wednesday, she was assigned the Twitter lawsuit which seeks to force Musk to complete his deal for the social media platform, which promises to be one of the biggest legal showdowns in years.
Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is joining its tech peers in a stock split. The trillion-dollar tech giant, which is the parent company of Google, plans to do a 20:1 stock split on Friday, July 15. If you're aiming to buy Alphabet before the stock split, the clock is ticking.
Rogers knows how to survive — and thrive — in turbulent times.
The market is unstable. Your portfolio doesn’t need to be.
Intel ( ) is the bearer of additional bad news. The chip giant will give an extra blow to consumers and businesses concerned about the health of the economy. For several weeks in fact, consumers have seen their bills for groceries and other products increase.
The deal talks are still on track but coming data and arbitration slowed the timeline, people familiar with the matter say.
We have an initial price objective but traders should be ready to pivot if the broad market averages falter.
To the oil industry, there is no single price of oil. Instead, there are multiple like Brent, Dubai, and WTI, each for a particular grade of crude. Russia has its own grade of oil—and its price is languishing.
Goldman Sachs slashed its earnings forecast for chipmakers and semiconductors due to fears of a slowdown in global growth.
Yahoo Finance Live checks out several of the day's trending stocks, including UnitedHealth Group's profit beat and gaming stocks popping off after an influx of Tiger Woods sports bets.
Shares of some of the world's biggest technology companies gained ground on Friday after several difficult sessions for the market. Semiconductor specialist Nvidia (NASDAQ: NVDA) was up as much as 2.4%, social media giant Meta Platforms (NASDAQ: META) rose as much as 3.7%, and customer relationship management (CRM) specialist Salesforce (NYSE: CRM) climbed as much as 3.8%. The catalyst that sent a wide swath of technology stocks higher today was a read on consumer spending, which was more robust than many had predicted.
Mining stocks could capitulate given waning demand for industrial metals
The head of the company now running the former McDonald's Corp chain of restaurants in Russia told RBC TV that producers of French fries are refusing to supply to the country and warned that attempts to increase domestic processing are fraught with difficulties. McDonald's quit Russia after a Western backlash against Moscow's military campaign in Ukraine, which included a barrage of economic sanctions, and sold all the restaurants it owned to a local licensee in May. CEO Oleg Paroev told Reuters the chain had sold almost 120,000 burgers on opening day.
Russia is positioning itself to engage in 'expropriation blackmail,' according to Mark Dixon, founder of the Moral Rating Agency.
Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, can sometimes be challenging, especially in today's market conditions. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the growth pote
Most retired workers depend on multiple streams of income during their retirement. Two of the most common such income streams are Social Security and pensions. If we look at pension vs. Social Security income, we find significant differences. Retired workers … Continue reading → The post Pension vs. Social Security: Key Differences appeared first on SmartAsset Blog.
Bill Gates has promised to give "virtually all" of his fortune away. Where will it go?
(Bloomberg) -- Former Treasury Secretary Lawrence Summers issued one of his harshest criticisms yet of the Federal Reserve’s slowness in moving to raise interest rates, and warned that policy makers are still presenting forecasts that are unrealistic.Most Read from BloombergIvana Trump, First Wife of Former President, Dies At 73Chinese Homebuyers Across 22 Cities Refuse to Pay MortgagesBiden to Leave Mideast With No Immediate Announcement on OilChina Growth Slows Sharply, Putting GDP Target Out
Home sale cancellations soared in June. But why?
Alphabet stock will undergo a 20-for-1 stock split on July 18. Here's how to trade the stock into the event.